<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950271</url>
  </required_header>
  <id_info>
    <org_study_id>GCCG7</org_study_id>
    <nct_id>NCT03950271</nct_id>
  </id_info>
  <brief_title>SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to observe the efficacy and safety of immume checkpoint inhibitor&#xD;
      PD-1 SHR1210 combined with Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy&#xD;
      of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, one-arm, phase II clinical study to evaluate the safety and&#xD;
      efficacy of SHR-1210 in combination with trastuzumab plus oxaliplatin and capecitabine for&#xD;
      HER2-positive locally advanced resectable gastric adenocarcinoma and gastroesophageal&#xD;
      junction adenocarcinoma during the perioperative treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival（DFS）</measure>
    <time_frame>up to 2 year</time_frame>
    <description>The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, and partial response (CR&#xD;
+ PR )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete response (pCR) rate</measure>
    <time_frame>up to 2 year</time_frame>
    <description>the rate of no residual invasive cancer, or only carcinoma in situ in both the excised breast and axillary lymph node</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine</intervention_name>
    <description>Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle&#xD;
postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles.</description>
    <arm_group_label>SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form&#xD;
&#xD;
          2. 18-75 years old&#xD;
&#xD;
          3. Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction&#xD;
             adenocarcinoma (cT4 or / and N+M0, MDT believes that perioperative treatment is&#xD;
             required):&#xD;
&#xD;
               1. No peritoneal metastasis in CT&#xD;
&#xD;
               2. evaluated as a resectable lesion. Note: Whether there is a distant metastasis&#xD;
                  should be confirmed by CT or MR scan. If bone metastasis is suspected, a bone&#xD;
                  scan should be performed. If there is suspected peritoneal metastasis, a&#xD;
                  laparoscopy should be performed. If brain metastasis is suspected, CT or MR&#xD;
                  examination should be performed.&#xD;
&#xD;
          4. Have not received cytotoxic chemotherapy or targeted therapy and local tumor resection&#xD;
&#xD;
          5. HER2 immunohistochemistry 3+ and fluorescence in situ hybridization showed significant&#xD;
             amplification&#xD;
&#xD;
          6. ECOG≤1&#xD;
&#xD;
          7. Tumor specimens that can be used to detect PD-L1 and MSI status can be provided.&#xD;
             Detection of PD-L1 and MSI will be performed after enrollment. This test requires&#xD;
             patients to provide paraffin-embedded biopsy specimens.&#xD;
&#xD;
          8. White blood cells ≥ 4×109/L, platelets without blood transfusion ≥ 100×109/L, absolute&#xD;
             neutrophil count (ANC) ≥ 1.5×109/L without granulocyte stimulating factor, hemoglobin&#xD;
             ≥ 90 g/L&#xD;
&#xD;
          9. bilirubin ≤ 1.5 times the upper limit of normal value, cereal grass and alanine&#xD;
             aminotransferase ≤ 2.5ULN. If there is liver metastasis, the grass and alanine&#xD;
             aminotransferase ≤ 5ULN.&#xD;
&#xD;
         10. serum creatinine ≤ 1.5ULN, or GFR &gt; 45 ml / min&#xD;
&#xD;
         11. serum albumin ≥ 25 g / L (2.5 g / dL)&#xD;
&#xD;
         12. INR or APTT ≤ 1.5 ULN&#xD;
&#xD;
         13. Hepatitis B surface antigen positive patients need to detect hepatitis B DNA virus&#xD;
             quantitative detection, only patients below the upper limit of normal detection can be&#xD;
             enrolled, and long-term use ofanti-hepatitis B virus drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to any test drug and its excipients, or have a history of severe allergies,&#xD;
             or a contraindication to test drugs&#xD;
&#xD;
          2. Have a history of autoimmune disease or be active&#xD;
&#xD;
          3. Previously received allogeneic bone marrow transplantation or organ transplantation&#xD;
&#xD;
          4. Congenital pulmonary fibrosis, drug-induced pneumonia, organizing pneumonia, or&#xD;
             CT-confirmed active pneumonia&#xD;
&#xD;
          5. HIV test positive&#xD;
&#xD;
          6. Active hepatitis B or hepatitis C&#xD;
&#xD;
          7. Active tuberculosis&#xD;
&#xD;
          8. Uncontrolled cancer pain&#xD;
&#xD;
          9. A live attenuated vaccine is injected within 4 weeks before the start of the study, or&#xD;
             it is expected that a live attenuated vaccine will be injected within 5 months after&#xD;
             the trial or the end of the trial.&#xD;
&#xD;
         10. Previous use of immunotherapy, including CTLA4, anti-PD-1, or anti-PDL1 mAb&#xD;
&#xD;
         11. Systemic application of glucocorticoids or immunosuppressants within 2 weeks prior to&#xD;
             the start of the trial. Inhaled corticosteroids and mineralocorticoids are allowed&#xD;
&#xD;
         12. Hormone use contraindications。&#xD;
&#xD;
         13. severe cardiovascular disease, myocardial infection or cerebrovascular accident,&#xD;
             arrhythmia, unstable angina within 3 months before the start of the test&#xD;
&#xD;
         14. Uncontrollable increase in blood pressure or elevated blood sugar&#xD;
&#xD;
         15. History of other malignant tumors 5 years ago, except for cervical cancer in situ,&#xD;
             non-melanoma skin cancer or stage I uterine cancer&#xD;
&#xD;
         16. Known central nervous system metastasis&#xD;
&#xD;
         17. ≥ NCI CTCAE Level 2 Peripheral Neuropathy&#xD;
&#xD;
         18. serum albumin is less than 2.5 g/dL&#xD;
&#xD;
         19. uncontrollable or symptomatic hypercalcemia&#xD;
&#xD;
         20. Infections requiring antibiotics within 14 days prior to the start of the test&#xD;
&#xD;
         21. chronic enteritis&#xD;
&#xD;
         22. clinically significant active gastrointestinal bleeding&#xD;
&#xD;
         23. Non-diagnostic surgery within 4 weeks prior to the start of the trial 24 There is&#xD;
             evidence of the need to limit any other disease using the test drug&#xD;
&#xD;
        25. Participate in other tests within 30 days before the start of the test, or plan to&#xD;
        participate in other tests during the test. Accept other experimental drugs within 28 days&#xD;
        before the start of the test 26. Women who are pregnant or lactating, or women who are&#xD;
        planning to become pregnant within 5 months of the end of treatment. Women of childbearing&#xD;
        age are required to undergo a blood pregnancy test within 7 days prior to the start of the&#xD;
        trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suxia Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, PhD</last_name>
      <phone>0086-13526501903</phone>
      <email>lining97@126.com</email>
    </contact>
    <investigator>
      <last_name>Ning Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suxia Luo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

